UBE2V1 and cancer: EGFR2, Lck3–5, MRP36, SART27, SART38–10, PTHrP11, TMEM189 (also referred as UBE2V)12, and WHSC212 were identified as common cancer antigens among various cancers, and epitope peptides from these antigens efficiently induced HLA-restricted cytotoxic T lymphocyte (CTL) responses in clinical trials13,14.